沃森生物 reported revenue of ¥0.83B for the period ended 2026-06-30, -27.7% year on year. Net income was ¥0.05B, a 5.5% net margin on a 68.8% gross margin. The largest revenue line is 疫苗产品 at 98% of the total. Free cash flow for the period was ¥0.13B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.83B | -27.7% |
| Gross profit | ¥0.57B | — |
| Operating income | ¥0.07B | — |
| Net income | ¥0.05B | — |
| Gross margin | 68.8% | Net margin 5.5% |
| Revenue Q/Q | -12.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 疫苗产品 | ¥0.82B | 97.8% |
| 合成生物制品 | ¥0.01B | 1.2% |
| 其他(补充) | ¥0.01B | 0.9% |
| 精准营养配方制品 | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.26B | 31.2% |
| R&D | ¥0.11B | 12.9% |
| SG&A | ¥0.41B | 49.4% |
| Tax & other | ¥0.03B | 3.3% |
| Item | Amount |
|---|---|
| Total assets | ¥10.50B |
| Total liabilities | ¥3.17B |
| Shareholders' equity | ¥7.33B |
| Equity / assets | 69.8% |
| Operating cash flow | ¥0.19B |
| Capital expenditure | ¥0.07B |
| Free cash flow | ¥0.13B |
| Cash conversion (OCF / net income) | 379% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
盈康生命 ・ 宋城演艺 ・ 南方泵业 ・ 汤臣倍健 ・ *ST香雪 ・ 天舟文化 ・ 睿智医药 ・ 世纪瑞尔 ・ 昌红科技 ・ *ST动力 ・ 科泰电源 ・ 瑞凌股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies